Davion Healthcare Plc, a leading medical device manufacturer, has granted a Global Manufacturing and Distribution Licence for its non-invasive BreastCheck™ home test for Breast Anomalies including Breast Cancer, to NeuRX Health Inc, a Rhode Island (USA) based company.
Under the terms of the agreement, NeuRX will pay Davion the sum of $120 Million USD for the licence, together with ongoing royalty payments on global sales of BreastCheck™. The licence is expected to be filed early January 2024.
Jack Kaye, Davion’s CEO, said: “We are thrilled to appoint NeuRx Health Inc as our global manufacturer and distributor for this important product. The team at NeuRX have extensive experience and expertise in both manufacturing and distribution internationally of medical products.”
BreastCheck™ is a non-invasive home test for Breast anomalies, including Breast Cancer. The home test takes just fifteen minutes, and the results are immediate. It is registered as a Class1 Medical Device with regulatory authorities in the USA (FDA), Europe (CE) and the United Kingdom (UKCA). BreastCheck™ will be available towards the end of the first quarter 2024 internationally, from Pharmacies, larger Retail Outlets and Online.
Robert Hainey, NeuRX CEO, added: “We are enthusiastic about the prospects this global licencing agreement gives us. Davion’s BreastCheck™ product is a global first, for which we expect there will be great demand internationally.”
The agreement follows on from Davion’s recent announcement of a $30 million IPO fundraising round alongside a NADAQ listing of the company’s ADRs through The Bank of New York Melon. Davion anticipates that the IPO and NASDAQ listing will take place in the first quarter of 2024, subject to market forces.
Munro Forbes, Davion’s Media Relations Manager, commented: “Our mission is to create and manage an environment for the secure development of new medical devices. With a current focus on accessible products available for self-use in the comfort of your own home utilising smart technology interfaces, we are committed to empowering individuals to take control of their health and well-being by providing them with the tools they need to detect potential health issues at an early stage. We just happen to make great medical devices that can make a difference in people’s lives.”
Today, Davion Healthcare Plc is pleased to announce the granting of a Global Manufacturing and Distribution Licence for its non-invasive BreastCheck™ home test for Breast Anomalies including Breast Cancer, to NeuRX Health Inc, a Rhode Island (USA) based company. Under the terms of the agreement, NeuRX will pay Davion the sum of $120 Million USD for the licence, together with ongoing royalty payments on global sales of BreastCheck™.
Jack Kaye, Davion’s CEO, said: “We are thrilled to appoint NeuRX Health Inc as our global manufacturer and distributor for this important product. The team at NeuRX have extensive experience and expertise in both manufacturing and distribution internationally of medical products.”
Robert Hainey, NeuRX CEO, added: “We are enthusiastic about the prospects this global licencing agreement gives us. Davion’s BreastCheck™ product is a global first, for which we expect there will be great demand internationally.”
The agreement follows on from Davion’s recent announcement of a $30 million IPO fundraising round alongside a NADAQ listing of the company’s ADRs through The Bank of New York Melon. Davion anticipates that the IPO and NASDAQ listing will take place in the first quarter of 2024, subject to market forces.
Munro Forbes, Davion’s Media Relations Manager, commented: “Our mission is to create and manage an environment for the secure development of new medical devices. With a current focus on accessible products available for self-use in the comfort of your own home utilising smart technology interfaces, we are committed to empowering individuals to take control of their health and well-being by providing them with the tools they need to detect potential health issues at an early stage. We just happen to make great medical devices that can make a difference in people’s lives.”
Today, Nicosia, Cyprus-based Davion Healthcare Plc has granted a Global Manufacturing and Distribution Licence for its non-invasive BreastCheck™ home test for Breast Anomalies including Breast Cancer, to Rhode Island (USA) based NeuRX Health Inc.
Under the terms of the agreement, NeuRX will pay Davion the sum of $120 Million USD for the licence, together with ongoing royalty payments on
